Holen Sie sich die Stockscreener-App
10.68
0.37%
-0.04
Schlusskurs vom Vortag:
$10.72
Offen:
$10.72
24-Stunden-Volumen:
3.96M
Relative Volume:
0.88
Marktkapitalisierung:
$7.62B
Einnahmen:
$125.68M
Nettoeinkommen (Verlust:
$4.81B
KGV:
1.8903
EPS:
5.65
Netto-Cashflow:
$-781.21M
1W Leistung:
+1.14%
1M Leistung:
-5.24%
6M Leistung:
-9.41%
1J Leistung:
-7.45%
1-Tages-Spanne:
$10.67
$10.86
1-Wochen-Bereich:
$10.55
$10.86
52-Wochen-Spanne:
$9.76
$13.05
Roivant Sciences Ltd Stock (ROIV) Company Profile
Firmenname
Roivant Sciences Ltd
Sektor
Branche
Telefon
441-295-5950
Adresse
CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON HM11
Vergleichen Sie ROIV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
10.68 | 7.62B | 125.68M | 4.81B | -781.21M | 5.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-01-05 | Eingeleitet | Piper Sandler | Overweight |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-17 | Eingeleitet | Guggenheim | Buy |
| 2023-06-08 | Eingeleitet | BofA Securities | Neutral |
| 2022-10-27 | Eingeleitet | JP Morgan | Overweight |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-12-15 | Eingeleitet | Goldman | Buy |
| 2021-11-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-28 | Eingeleitet | Citigroup | Buy |
| 2021-10-26 | Eingeleitet | Cowen | Outperform |
| 2021-10-26 | Eingeleitet | Jefferies | Buy |
| 2021-10-26 | Eingeleitet | Truist | Buy |
Alle ansehen
Roivant Sciences Ltd Aktie (ROIV) Neueste Nachrichten
Roivant Sciences appoints new Principal Accounting Officer By Investing.com - Investing.com South Africa
Roivant Sciences appoints new Principal Accounting Officer - Investing.com
Roivant Sciences Appoints New Chief Accounting Officer - TipRanks
Will Moderna Stock Drop to $25? 1 Wall Street Analyst Thinks So. - The Motley Fool
Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) CAO Sells 227,500 Shares of Stock - MarketBeat
Long Term Trading Analysis for (ROIV) - Stock Traders Daily
Roivant Sciences' chief accounting officer sells $2.37 million in shares By Investing.com - Investing.com Canada
Roivant Sciences’ chief accounting officer sells $2.37 million in shares By Investing.com - Investing.com Nigeria
Roivant Sciences' chief accounting officer sells $2.37 million in shares - Investing.com India
Eric Venker Sells 218,041 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) Stock - MarketBeat
Roivant Sciences president Eric Venker sells over $4.56 million in stock - MSN
Roivant Sciences president Eric Venker sells over $4.56 million in stock By Investing.com - Investing.com South Africa
Roivant Sciences (NASDAQ:ROIV) Shares Gap Up After Earnings Beat - MarketBeat
Roivant Sciences' (ROIV) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
178,853 Shares in Roivant Sciences Ltd. (NASDAQ:ROIV) Acquired by Elevate Capital Advisors LLC - MarketBeat
Roivant Sciences (NASDAQ:ROIV) Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
Roivant Sciences: Earnings Reveal Strategic Clinical Advances - MSN
Roivant Sciences targets brepocitinib expansion with new cutaneous sarcoidosis trial amid $5.2B cash position - MSN
Roivant Sciences price target lowered to $12 from $13 at BofA - Yahoo Finance
Roivant Sciences Ltd. (ROIV): A Cheap Biotech Stock to Invest In Now - Yahoo Finance
Roivant Sciences Insiders Sold US$52m Of Shares Suggesting Hesitancy - Simply Wall St
News Flash: Analysts Just Made A Captivating Upgrade To Their Roivant Sciences Ltd. (NASDAQ:ROIV) Forecasts - Yahoo Finance
Industry Analysts Just Upgraded Their Roivant Sciences Ltd. (NASDAQ:ROIV) Revenue Forecasts By 21% - Simply Wall St
10 Cheap Biotech Stocks to Invest in Now - Insider Monkey
Roivant Sciences Ltd. (NASDAQ:ROIV) Q3 2024 Earnings Call Transcript - Insider Monkey
Roivant Sciences Tops Q3 Expectations - Mitrade
Roivant Sciences: Strong Earnings Call Amid Challenges - TipRanks
Roivant Sciences Ltd (ROIV) Q3 2024 Earnings Call Highlights: Strategic Moves and Financial ... By GuruFocus - Investing.com Canada
Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Tops Revenue Estimates - MSN
Roivant Sciences Ltd. (ROIV) reports earnings - Quartz
Roivant Sciences earnings beat by $0.48, revenue topped estimates - Investing.com Australia
Roivant Sciences Ltd. (ROIV) Tops Q3 EPS by 48c - StreetInsider.com
Roivant Reports Financial Results for Q3 2024 - TradingView
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update - The Manila Times
Roivant Sciences Fiscal Q3 Earnings, Revenue Fall -February 10, 2025 at 07:17 am EST - Marketscreener.com
Roivant Sciences Q3 Earnings Assessment - Benzinga
Earnings Flash (ROIV) Roivant Sciences Posts Q3 Revenue $9M, vs. FactSet Est of $5M - Marketscreener.com
Roivant's $5.2B War Chest Fuels Ambitious Clinical Pipeline as Loss Widens in Q3 - StockTitan
Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Sold by DAVENPORT & Co LLC - MarketBeat
Trading (ROIV) With Integrated Risk Controls - Stock Traders Daily
Roivant Sciences (ROIV) to Release Quarterly Earnings on Monday - Defense World
Finanzdaten der Roivant Sciences Ltd-Aktie (ROIV)
Umsatz
Nettogewinn
Free Cashflow
ENV
Roivant Sciences Ltd-Aktie (ROIV) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Kumar Rakhi | Chief Accounting Officer |
Feb 13 '25 |
Option Exercise |
3.85 |
187,500 |
721,875 |
390,764 |
| Kumar Rakhi | Chief Accounting Officer |
Feb 13 '25 |
Sale |
10.43 |
227,500 |
2,372,825 |
163,264 |
| Venker Eric | President & COO |
Feb 12 '25 |
Option Exercise |
3.85 |
300,000 |
1,155,000 |
1,032,294 |
| Venker Eric | President & COO |
Feb 13 '25 |
Option Exercise |
3.85 |
300,000 |
1,155,000 |
1,114,910 |
| Venker Eric | President & COO |
Feb 12 '25 |
Sale |
10.53 |
217,384 |
2,289,054 |
732,294 |
| Venker Eric | President & COO |
Feb 13 '25 |
Sale |
10.42 |
218,041 |
2,271,987 |
896,869 |
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):